Related Experiment Video
Updated: Jun 10, 2025
09:12
Nanoparticle-mediated siRNA Gene-silencing in Adult Zebrafish Heart
Published on: July 29, 2018
8.1K
Emerging RNAi Therapies to Treat Hypertension
Pawan Daga1, Gurnoor Singh2, Tushar Menon2
1Department of Internal Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Molecular Diagnosis & Therapy
|October 14, 2024
Summary
Ribonucleic acid interference (RNAi) offers a novel approach to treating hypertension (HTN). This gene-silencing technology shows promise for long-term blood pressure control with infrequent dosing and minimal side effects.
Area of Science:
- Biotechnology
- Genetics
- Cardiovascular Medicine
Background:
- Hypertension (HTN) affects over 1.3 billion people globally, posing a major cardiovascular risk.
- Suboptimal blood pressure (BP) control is driven by aging, obesity, poor diet, and adherence issues.
- Novel therapeutic strategies are crucial for effective long-term hypertension management.
Purpose of the Study:
- To systematically review the role of Ribonucleic acid interference (RNAi) in hypertension management.
- To evaluate RNAi's mechanisms, clinical utility, and safety profile for antihypertensive effects.
- To highlight early-phase trial data and challenges associated with RNAi therapy.
Main Methods:
- Systematic literature review of peer-reviewed articles.
- Searches conducted in PubMed, EMBASE, and Scopus databases.
- Focus on studies investigating RNAi for hypertension, including mechanisms, efficacy, and safety.
Main Results:
- RNAi technology leverages natural gene silencing for potential therapeutic benefits.
- Early-phase trials indicate promise, but challenges like target specificity and delivery exist.
- RNAi demonstrates potential for long-term action and infrequent dosing.
Conclusions:
- RNAi therapy presents a significant potential role in managing hypertension.
- Unique benefits include long duration of action and infrequent dosing.
- RNAi therapy shows a favorable safety profile with a lack of major side effects.
Related Concept Videos
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
02:30siRNA - Small Interfering RNAs
16.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.6K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
505
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
505
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
595
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
595